HTA57 Quantifying Heterogeneity within and between Treatment Guidelines for Type 2 Diabetes: Potential Implications for EU-Wide Health Technology Assessment

Abstract

By 2030, the European Union (EU) will require manufacturers to submit a Joint Clinical Assessment (JCA) dossier for new therapies, aiming to harmonize health technology assessment across the EU. This will require all 27 member states to define relevant PICO (population, intervention, comparator, outcome) requirements. In type 2 diabetes (T2D), step-wise intensification is often required to maintain glycemic control, with recommendations at each therapy line creating branched treatment pathways. This review quantifies the heterogeneity in managing T2D in EU guidelines and the implications for the JCA process.